ERBB2 and acute lymphoblastic leukemia: Some of the most effective approved by the FDA are Brentuximab Vedotin for Hodgkin’s lymphoma and anaplastic large cell lymphoma, ado-trastuzumab emtansine for HER2-positive metastatic breast cancer and inotuzumab ozogamicin for specific types of acute lymphoblastic leukemia (ALL) in adults and children.